Prophylactic Effects of Dairy Kluyveromyces marxianus YAS through Overexpression of BAX, CASP 3, CASP 8 and CASP 9 on Human Colon Cancer Cell Lines

Authors: Amir Saber Gharamaleki, Beitollah Alipour, Zeinab Faghfoori, Ahmad YariKhosroushahi

Abstract:

Colorectal cancer (CRC) is one of the most prevalent cancers and intestinal microbial community plays an important role in colorectal tumorigenesis. Probiotics have recently been assessed as effective anti-proliferative agents and thus this study was performed to examine whether CRC undergo apoptosis by treating with isolated Iranian native dairy yeast, Kluyveromyces marxianus YAS, secretion metabolites. The cytotoxicity assessments on cells (HT-29, Caco-2) were accomplished through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as well as qualitative DAPI (4',6-diamidino-2-phenylindole staining) and quantitative (flow cytometry assessments) evaluations of apoptosis. To evaluate the main mechanism of apoptosis, Real time PCR method was applied. Kluyveromyces marxianus YAS secretions (IC50) showed significant cytotoxicity against HT-29 and Caco-2 cancer cell lines (66.57 % and 66.34 % apoptosis) similar to 5-Fluorouracil (5-FU) while apoptosis only was developed in 27.57 % of KDR normal cells. The prophylactic effects of Kluyveromyces marxianus (PTCC 5195), as a reference yeast, was not similar to Kluyveromyces marxianus YAS indicating strain dependency of bioactivities on CRC disease prevention. Based on real time PCR results, the main cytotoxicity is related to apoptosis phenomenon and the core related mechanism is depended on the overexpression of BAX, CASP 9, CASP 8 and CASP 3 inducing apoptosis genes. However, several investigations should be conducted to precisely determine the effective compounds to be used as anticancer therapeutics in the future.

Keywords: Anticancer, anti-proliferative, apoptosis, cytotoxicity, yeast.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1112047

References:

[1] Liboredo JC, Anastácio LR, Pelúzio MdCG, Valente FX, Penido LCP, Nicoli JR, et al. Effect of probiotics on the development of dimethylhydrazine-induced preneoplastic lesions in the mice colon. Acta Cirurgica Brasileira. 2013;28(5):367-72.
[2] McCormack V, Boffetta P. Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low-and middle-income countries. Annals of Oncology. 2011:mdq763.
[3] Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer. ecancermedicalscience. 2015;9.
[4] Yao Y-L, Shao J, Zhang C, Wu J-H, Zhang Q-H, Wang J-J, et al. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. 2013.
[5] Ciernikova S, Mego M, Hainova K, Adamcikova Z, Stevurkova V, Zajac V. Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer? Neoplasma. 2014;62(3):345-52.
[6] Zhong L, Zhang X, Covasa M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J Gastroenterol. 2014;20(24):7878-86.
[7] Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Frontiers in microbiology. 2015;6.
[8] Zhu Y, Luo TM, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer letters. 2011;309(2):119-27.
[9] Rafter J. Lactic acid bacteria and cancer: mechanistic perspective. British Journal of Nutrition. 2002;88(S1):S89-S94.
[10] Mizock BA. Probiotics. Disease-a-month: DM. 2015;61(7):259-90.
[11] Burns A, Rowland I. Anti-carcinogenicity of probiotics and prebiotics. Current issues in intestinal microbiology. 2000;1(1):13-24.
[12] Rowland IR, Gangolli SD. Role of gastrointestinal flora in the metabolic and toxicological activities of xenobiotics. General and Applied Toxicology. 2nd Edition ed. Macmillan Publishers Ltd, London, p1999. p. 561-76.
[13] Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel M-T, Corcos L, Jan G. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One. 2012;7(3):e31892.
[14] Ghoneum M, Hamilton J, Brown J, Gollapudi S. Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer research. 2005;25(2a):981-9.
[15] Ghoneum M, Gollapudi S. Modified arabinoxylan rice bran (MGN-3/Biobran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. Anticancer research. 2005;25(2a):859-70.
[16] Ghoneum M, Wang L, Agrawal S, Gollapudi S. Yeast therapy for the treatment of breast cancer: a nude mice model study. In vivo (Athens, Greece). 2007;21(2):251-8.
[17] Badr El-Din NK, Noaman E, Ghoneum M. In Vivo Tumor Inhibitory Effects of Nutritional Rice Bran Supplement MGN-3/Biobran on Ehrlich Carcinoma-Bearing Mice*. Nutrition and cancer. 2008;60(2):235-44.
[18] Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71(2):766-73.
[19] Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O'Brien M, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. Journal of Biological Chemistry. 2006;281(34):24449-54.
[20] Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139.
[21] Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-7.
[22] Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. Journal of cellular biochemistry. 1998;70(1):1-7.
[23] De Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol. 1998;184(1):53-7.
[24] Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res. 2000;78:31-101.
[25] Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer research. 2002;62(2):488-96.
[26] Moshnikova AB, Moshnikov SA, Afanasyev VN, Krotova KE, Sadovnikov VB, Beletsky IP. Cell death induced by chemical homobifunctional cross-linkers. Cross-linker induced apoptosis. The international journal of biochemistry & cell biology. 2001;33(12):1160-71.
[27] Liu Y, Song XD, Liu W, Zhang TY, Zuo J. Glucose deprivation induces mitochondrial dysfunction and oxidative stress in PC12 cell line. Journal of cellular and molecular medicine. 2003;7(1):49-56.
[28] Katayama K, Dobashi Y, Kitagawa M, Kawai M, Kadoya Y, Kameya T. Cdk4/cyclin D1 kinase, a universal and critical regulator of apoptosis. Anticancer research. 2003;23(1a):235-43.
[29] Elmore S. Apoptosis: a review of programmed cell death. Toxicologic pathology. 2007;35(4):495-516.
[30] Hickman JA. Apoptosis induced by anticancer drugs. Cancer and Metastasis Reviews. 1992;11(2):121-39.
[31] Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011;2(3):222.
[32] Ghoneum M, Matsuura M, Braga M, Gollapudi S. S. cerevisiae induces apoptosis in human metastatic breast cancer cells by altering intracellular Ca2+ and the ratio of Bax and Bcl-2. International journal of oncology. 2008;33(3):533-9.
[33] Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and Molecular Targeting Therapy in Cancer. BioMed Research International. 2014;2014:150845.
[34] Oliveira RJ, Salles MJ, da Silva AF, Kanno TY, Lourenco AC, Leite Vda S, et al. In vivo evaluation of the antimutagenic and antigenotoxic effects of beta-glucan extracted from Saccharomyces cerevisiae in acute treatment with multiple doses. Genet Mol Biol. 2013;36(3):413-24.
[35] Ghoneum M, Gollapudi S. Induction of apoptosis in breast cancer cells by Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer research. 2004;24(3A):1455-64.
[36] Ghoneum M, El-Din NKB, Noaman E, Tolentino L. Saccharomyces cerevisiae, the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice. Cancer Immunology, Immunotherapy. 2008;57(4):581-92.
[37] Garofalo C, Osimani A, Milanovic V, Aquilanti L, De Filippis F, Stellato G, et al. Bacteria and yeast microbiota in milk kefir grains from different Italian regions. Food microbiology. 2015;49:123-33.
[38] Harju S, Fedosyuk H, Peterson KR. Rapid isolation of yeast genomic DNA: Bust n' Grab. BMC Biotechnol. 2004;4:8.
[39] Gardes M, Bruns TD. ITS primers with enhanced specificity for basidiomycetes‐application to the identification of mycorrhizae and rusts. Molecular ecology. 1993;2(2):113-8.
[40] National Center for Biotechnology Information (NCBI). Available from: http://www.ncbi.nlm.nih.gov/BLAST.
[41] PREMIER Biosoft. Retrieved January 23, 2016, from http://www.premierbiosoft.com/
[42] Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Research. 2001;29(9):e45-e.
[43] Deng W, Xi D, Mao H, Wanapat M. The use of molecular techniques based on ribosomal RNA and DNA for rumen microbial ecosystem studies: A review. Molecular Biology Report. 2008;35:265-74.
[44] Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. Journal of the American dietetic association. 2008;108(3):510-21.
[45] Kumar H, Salminen S, Verhagen H, Rowland I, Heimbach J, Bañares S, et al. Novel probiotics and prebiotics: road to the market. Current opinion in biotechnology. 2015;32:99-103.
[46] Barzegari A, Saei AA. Designing probiotics with respect to the native microbiome. Future microbiology. 2012;7(5):571-5.
[47] Lopandic K, Zelger S, Banszky LK, Eliskases-Lechner F, Prillinger H. Identification of yeasts associated with milk products using traditional and molecular techniques. Food Microbiol. 2006;23(4):341-50.
[48] Kumura H, Tanoue Y, M T, Tanaka T, Shimazaki K. Screening of dairy yeast strains for probiotic applications. J Dairy Science. 2004;87:4050-6.
[49] Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, et al. Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in apcmin mice. Gastroenterology. 2009;137(3):914-23.
[50] Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104-19.
[51] Fleet G, Balia R. The public health and probiotic significance of yeasts in foods and beverages. Yeasts in Food and Beverages: Springer; 2006. p. 381-97.
[52] Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol. 2007;23(6):679-92.
[53] Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000; 2(6):681-6.
[54] McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG. 2010;16(18):2202.
[55] Marteau P, Boutron-Ruault M. Nutritional advantages of probiotics and prebiotics. British Journal of Nutrition. 2002;87(S2):S153-S7.
[56] Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and immunity. 1996;64(12):5225-32.
[57] Gedek B. Adherence of Escherichia coli serogroup 0 157 and the Salmonella Typhimurium mutant DT 104 to the surface of Saccharomyces boulardii Adhärenz von Escherichia coli Serogruppe 0 157 und von der Salmonella Typhimurium-Mutante DT 104 an der Oberfläche. mycoses. 1999;42:261-4.
[58] Philpott DJ, McKay DM, Sherman PM, Perdue MH. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol. 1996;270(4 Pt 1):G634-45.
[59] Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, et al. Saccharomyces boulardii Stimulates Intestinal Immunoglobulin A Immune Response to Clostridium difficileToxin A in Mice. Infection and immunity. 2001;69(4):2762-5.
[60] Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron J-F, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131(6):1812-25.
[61] Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420-30.
[62] Rogalska A, Szwed M, Jóźwiak Z. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2010;700(1):1-10.
[63] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
[64] Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Current Opinion in Genetics & Development. 1996;6(1):45-9.
[65] Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature reviews Cancer. 2003;3(7):502-16.
[66] Ashkenazi A, Pai RC, Fong S. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
[67] Yang B, McCullough ML, Gapstur SM, Jacobs EJ, Bostick RM, Fedirko V, et al. Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: the Cancer Prevention Study-II Nutrition Cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(22):2335-43.
[68] Habil N, Abate W, Beal J, Foey AD. Heat-killed probiotic bacteria differentially regulate colonic epithelial cell production of human beta-defensin-2: dependence on inflammatory cytokines. Beneficial microbes. 2014;5(4):483-95.
[69] Mee YH, Navindra PS, Yanjun Z, David H. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells Journal of Nutritional Biochemistry. 2008;19 448-58.